Delamination resistant glass containers with heat-tolerant coatings

Patent metadata

Field	Value
Publication number	US-10787292-B2
Application number	US-201715656721-A
Country	US
Kind code	B2
Filing date	Jul 21, 2017
Priority date	Jun 28, 2012
Publication date	Sep 29, 2020
Grant date	Sep 29, 2020

Abstract

Disclosed herein are delamination resistant glass pharmaceutical containers which may include an aluminosilicate glass having a Class HGA 1 hydrolytic resistance when tested according to ISO 720-1985 testing standard. The glass containers may also have a compressive stress layer with a depth of layer of greater than 25 μm. A surface compressive stress of the glass containers may be greater than or equal to 350 MPa. The delamination resistant glass pharmaceutical containers may be ion exchange strengthened and the ion exchange strengthening may include treating the delamination resistant glass pharmaceutical container in a molten salt bath for a time less than or equal to 5 hours at a temperature less than or equal to 450° C.

First claim

What is claimed is:

1. A glass pharmaceutical container comprising:
an aluminosilicate glass having a Class HGA 1 hydrolytic resistance when tested according to ISO 720-1985 testing standard, the aluminosilicate glass comprising greater than 70 mol. % and less than or equal to 80 mol. % of SiO 2 , the aluminosilicate glass comprising X mol. % of Al 2 O 3 and Y mol. % of alkali oxides and a ratio Y:X is greater than or equal to about 1 and less than or equal to about 2, the aluminosilicate glass comprising CaO and MgO in amounts such that a molar ratio of CaO/(CaO+MgO) is less than 0.5, and wherein a molar ratio of B 2 O 3 /(Y−X) in the aluminosilicate glass composition is from 0 to 0.3;
a compressive stress layer with a depth of layer of greater than 25 μm; and
a surface compressive stress of greater than or equal to 350 MPa, wherein the glass pharmaceutical container is ion exchange strengthened and the ion exchange strengthening comprises treating the glass pharmaceutical container in a molten salt bath for a time less than or equal to 5 hours at a temperature less than or equal to 450° C.

2. The glass pharmaceutical container of claim 1 , wherein the glass pharmaceutical container has a Type HGA1 hydrolytic resistance according to ISO 720:1985 after ion exchange strengthening.

3. The glass pharmaceutical container of claim 1 , wherein the glass pharmaceutical container has a threshold diffusivity of greater than 16 μm 2 /hr at a temperature of less than or equal to 450° C.

4. The glass pharmaceutical container of claim 1 , wherein the glass pharmaceutical container has a threshold diffusivity of greater than or equal to 20 μm 2 /hr at a temperature of less than or equal to 450° C.

5. The glass pharmaceutical container of claim 1 , wherein the glass pharmaceutical container is free of boron and compounds of boron.

6. The glass pharmaceutical container of claim 1 , wherein a concentration of B 2 O 3 in the glass pharmaceutical container is greater than or equal to about 0.01 mol. %.

7. The glass pharmaceutical container of claim 6 , wherein the concentration of B 2 O 3 in the glass pharmaceutical container is less than about 4 mol. %.

8. A glass pharmaceutical container comprising at least one of:
a Type HGB1 hydrolytic resistance according to ISO 719:1985;
at least a Class A2 base resistance or better according to ISO 695:1991; or
at least a Class S2 acid resistance according to DIN 12116:2001; and
the glass pharmaceutical container has a compressive stress layer with a depth of layer of greater than 25 μm;
a glass composition comprising greater than 70 mol. % and less than or equal to 80 mol. % SiO 2 , the glass composition comprising X mol. % of Al 2 O 3 and Y mol. % of alkali oxides and a ratio Y:X is greater than or equal to about 1 and less than or equal to about 2, the glass composition comprising CaO and MgO in amounts such that a molar ratio of CaO/(CaO+MgO) is less than 0.5, and a molar ratio of B 2 O 3 /(Y−X) in the glass composition is from 0 to 0.3; and
a surface compressive stress of greater than or equal to 200 MPa, wherein the glass pharmaceutical container is ion exchange strengthened and the ion exchange strengthening comprises treating the glass pharmaceutical container in a molten salt bath for a time less than or equal to 10 hours at a temperature less than or equal to 450° C.

9. The glass pharmaceutical container of claim 8 , wherein the glass pharmaceutical container is free from boron and compounds of boron.

10. The glass pharmaceutical container of claim 8 , wherein a concentration of B 2 O 3 in the glass pharmaceutical container is greater than or equal to about 0.01 mol. %.

11. The glass pharmaceutical container of claim 10 , wherein the concentration of B 2 O 3 in the glass pharmaceutical container is less than about 4 mol. %.

12. The glass pharmaceutical container of claim 8 , wherein the surface compressive stress is greater than or equal to 250 MPa.

13. A glass pharmaceutical container comprising at least one of:
a Type HGB1 hydrolytic resistance according to ISO 719:1985; or
a Type HGA1 hydrolytic resistance according to ISO 720:1985;
wherein the pharmaceutical container is ion exchange strengthened and comprises a compressive stress layer with a depth of layer of greater than 15 μm and a surface compressive stress of greater than or equal to 350 MPa;
wherein the ion exchange strengthening comprises treating the pharmaceutical container in a molten salt bath for a time less than or equal to 10 hours at a temperature less than or equal to 500° C.; and
wherein the glass pharmaceutical container comprises a glass composition which is free from boron and compounds of boron such that the glass pharmaceutical container does not delaminate, the glass composition comprising X mol. % of Al 2 O 3 and Y mol. % of alkali oxides and a ratio Y:X is greater than or equal to about 1 and less than or equal to about 2, the glass composition comprising CaO and MgO in amounts such that a molar ratio of CaO/(CaO+MgO) is less than 0.5.

14. The glass pharmaceutical container of claim 13 , wherein the glass pharmaceutical container has a threshold diffusivity of greater than 16 μm 2 /hr at a temperature of less than or equal to 450° C.

15. The glass pharmaceutical container of claim 13 , wherein the glass pharmaceutical container has a threshold diffusivity of greater than or equal to 20 μm 2 /hr at a temperature of less than or equal to 450° C.

Assignees

• Corning Inc

Inventors

• Adib Kaveh
• Bookbinder Dana Craig
• Chang Theresa
• Danielson Paul Stephen
• Demartino Steven Edward
• Drake Melinda Ann
• Fadeev Andrei Gennadyevich
• Hamilton James Patrick
• Morena Robert Michael
• Pal Santona
• Peanasky John Stephen
• Saha Chandan Kumar
• Schaut Robert Anthony
• Schiefelbein Susan Lee
• Timmons Christopher Lee

Classifications

• C03C21/002

  to perform ion-exchange between alkali ions (C03C21/005 takes precedence) · CPC title

• C03C17/42

  at least one coating of an organic material and at least one non-metal coating · CPC title

• C03C17/3405

  with at least two coatings of organic materials (C03C17/36, C03C17/42 take precedence) · CPC title

• C03C17/32

  with synthetic or natural resins (C03C17/30 takes precedence) · CPC title

• C03C17/30

  with silicon-containing compounds · CPC title